RRM2 Regulates Sensitivity to Sunitinib and PD‐1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway

Modeling clear cell renal cell carcinoma and therapeutic implications

(2020) Melissa M. Wolf et al.   ONCOGENE

New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies

(2020) Marc-Oliver Grimm et al.   Journal of Clinical Medicine

Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells

(2020) Pei-Ming Yang et al.   Biomolecules

Downregulation of RRM2 Attenuates Retroperitoneal Liposarcoma Progression via the Akt/mTOR/4EBP1 Pathway: Clinical, Biological, and Therapeutic Significance

(2020) Sha Zhang et al.   OncoTargets and Therapy

The lncRNA lincNMR regulates nucleotide metabolism via a YBX1 - RRM2 axis in cancer

(2020) Minakshi Gandhi et al.   Nature Communications

Inhibiting RRM2 to enhance the anticancer activity of chemotherapy

(2020) Yaqiong Zhan et al.   BIOMEDICINE & PHARMACOTHERAPY

RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer

(2020) Yueyue Yang et al.   Cancer Cell International

A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)

(2019) Ying Z. Mazzu et al.   CLINICAL CANCER RESEARCH

Acetylation regulates ribonucleotide reductase activity and cancer cell growth

(2019) Guo Chen et al.   Nature Communications

LncRNA AFAP1-AS1 Supresses miR-139-5p and Promotes Cell Proliferation and Chemotherapy Resistance of Non-small Cell Lung Cancer by Competitively Upregulating RRM2

(2019) Na Huang et al.   Frontiers in Oncology

Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma

(2018) Yongchang Lai et al.   Cancer Cell International

Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies

(2018) Peter Makhov et al.   MOLECULAR CANCER THERAPEUTICS

NT5E inhibition suppresses the growth of sunitinib-resistant cells and EMT course and AKT/GSK-3β signaling pathway in renal cell cancer

(2018) Dan Peng et al.   IUBMB LIFE

Annexin A1-suppressed autophagy promotes nasopharyngeal carcinoma cell invasion and metastasis by PI3K/AKT signaling activation

(2018) Jin-Feng Zhu et al.   Cell Death & Disease

Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade

(2017) Kei Ishibashi et al.   Oncotarget

The promising role of nivolumab in renal cell cancers

(2016) Kanika Gupta et al.   CANCER BIOLOGY & THERAPY

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance

(2016) K. Berns et al.   CLINICAL CANCER RESEARCH

A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study

(2016) Mark H. Kirschbaum et al.   LEUKEMIA & LYMPHOMA

Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action

(2016) I. Duran et al.   Targeted Oncology

HPV16 E6 regulates annexin 1 (ANXA1) protein expression in cervical carcinoma cell lines

(2016) Marilia Freitas Calmon et al.   VIROLOGY

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma

(2015) C-F Xu et al.   BRITISH JOURNAL OF CANCER

Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation

(2015) Sophia X. Pfister et al.   CANCER CELL

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma

(2015) Y Zhu et al.   Cell Death & Disease

Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB

(2015) Kavitha Gowrishankar et al.   PLoS One

Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA

(2014) J. E. Zuckerman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Small-Molecule Blocking Ribonucleotide Reductase Holoenzyme Formation Inhibits Cancer Cell Growth and Overcomes Drug Resistance

(2013) B. Zhou et al.   CANCER RESEARCH

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

(2012) X. Jiang et al.   CLINICAL CANCER RESEARCH

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

(2010) D. Huang et al.   CANCER RESEARCH

Annexin-1 signals mitogen-stimulated breast tumor cell proliferation by activation of the formyl peptide receptors (FPRs) 1 and 2

(2010) Thippadey Khau et al.   FASEB JOURNAL